ASCO 2020: Biomarkers for immunotherapy treatment for advanced kidney cancer
Biomarkers enable doctors predict which patients will respond to which [...]
ASCO 2020: HIF-2 alpha inhibitor induced positive response for VHL-associated kidney cancer
Results from a phase II international trial led by researchers [...]
ASCO 2020: Factors influencing outcomes in kidney cancer treated with immunotherapy
A study presented during the 2020 American Society of Clinical [...]
ASCO 2020: Pembrolizumab/axitinib combination for the treatment of advanced kidney cancer
Updated results from the KEYNOTE-426 study of pembrolizumab plus axitinib [...]
ASCO 2020: Savolitinib is promising for the treatment of papillary renal cell carcinoma
In a study presented during the 2020 American Society of [...]
Combination of vaccinia virus plus immune checkpoint inhibitor for advanced kidney cancer
Results from a phase Ib study of a vaccinia virus [...]
Long-term outcomes after radiofrequency ablation
A recent study published in Cancers this month provides evidence [...]
Axitinib effective as a third-line treatment for kidney cancer
A recent study published in the journal In Vivo assessed [...]
Promising efficacy and safety of seleno-L-methionine plus axitinib in advanced kidney cancer
Data from a recent phase I study of seleno-L-methionine in [...]
Evidence in favour of active surveillance for small renal masses
Two studies presented at the American Urological Association 2020 Virtual [...]
